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Signs	&	Symptoms
Multiple	Myeloma
Anne	Doup	BSN,	RN,	ATC,	RNFA
Multiple	Myeloma
What	&	Why
• Multiple	myeloma	[MM]	is	a	complex	
hematologic	malignancy.	It	is	crucial	
for	any	practitioner	to	be	aware	of	the	
pathophysiology,	presenting	clinical	
manifestations,	differential	diagnoses,	
implications	for	care,	and	other	
disease	specific	details	to	avoid	
misdiagnosis	and	provide	proper	
treatment/referral.	
• As	a	future	nurse	practitioner	
providing	care	in	an	orthopedic	office	
in	addition	to	the	surgical	environment	
there	is	a	high	likelihood	of	caring	for	a	
patient	with	this	disease.
• American	Cancer	Society	(2018)	
Estimates:
Ø “30,770	newly	diagnosed	cases	of	
MM	in	the	United	States
Ø 12,770	deaths
Ø 1	out	of	132	life	time	risk	of	
developing	MM”	(p.1)
Presentation:	Multiple	
Myeloma
• Plasma	cell	malignancy,	insidious	onset
• Malignant	plasma	cells	multiply	in	
bone	marrow	and	produce	an	
overabundance	of	monoclonal	protein	
(Michels &	Peterson,	2017).
• Monoclonal	protein	produced:	IgG,	
IgM,	IgA	(most	commonly).	IgE,	IgD	
(rarely).	Kappa	or	Lambda	light	chain	
proteins	(Michels	&	Peterson,	2017).
• African	Americans	are	twice	as	likely	
to	develop	MM	compared	to	
Caucasians.	African	Americans	also	
present	earlier	in	life	(Michels	&	
Peterson,	2017).
• 85%	of	patients	diagnosed	with	MM	
are	older	than	65	years	(Michels	&	
Peterson,	2017).
• 65	years	old	is	current	median	age	of	
diagnosis	(Brigle	&	Rogers,	2017).
• 46.6%	5	year	survival	rate	(Brigle	&	
Rogers,	2017).
• Findings	on	presentation	for	patients	
with	multiple	myeloma	presented	in	
Table	1	(Michels	&	Peterson,	2017).
• World	Health	Organization	
Classification,	differentiation	between:
1.	Multiple	myeloma	[MM]
2.	Monoclonal	gammopathy	of
undetermined	significance
[MGUS]
3.	Solitary	plasmacytoma	of	the					
bone
4.	Extraosseus	plasmacytoma
5.	Monoclonal	immunoglobulin			
deposition	diseases
(Brigle	&	Rogers,	2017)
Underlying	Pathophysiology Conclusion
Providers	should	be	aware	of	evaluation	
and	management	of	MM	in	relation	to	other	
plasma	cell	dyscrasias	for	prompt	diagnosis	
and	treatment.	Refer	to	Figure	1	in	the	
March	2017	American	Family	Physician	
Journal	Article,	Volume	95,	Number	6,	
Multiple	Myeloma:	Diagnosis	and	
Treatment	for an	excellent	flowchart	to	
assist	with	management	and	treatment	
(Michels	&	Peterson,	2017).
Providers	should	also	be	aware	of	plasma	
cell	diseases	that	progress	to	MM	(MGUS	
and	Smoldering	MM)	(Brigle	&	Rogers,	
2017).
Overall	diagnostic	workup	for	suspicion	
of	MM	includes,	“lab	studies,	urine	studies,	
bone	marrow	biopsy,	and	radiographic	
evaluation”	(Brigle	&	Rogers,	2017,	p.231).		
For	specific	diagnostics	refer	to	Seminars	
in	Oncology	Nursing	Volume	33,	Number	3,	
Pathobiology	and	Diagnosis	of	Multiple	
Myeloma	(Brigle	&	Rogers,	2017,	Table	7,	p.	
231).
Current	findings	confirm	survival	
improvements	for	patients	with	MM.	
• Populations	that	should	be	considered	
regarding	survival	improvement:	older	
populations	(75+	years)	and	minority	
populations	(Costa	et	al.,	2016)
Significant	expansion	of	molecular	
pathophysiology	of	MM	over	the	last	
decade	has	allowed	progression	of	study	of	
various	MM	pathogenesis	pathways	
(Lawasut	et	al.,	2013).
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Plasma	Cell	Disease:	
Incurable,	Heterogeneous
• Monoclonal	plasma	cell	crowding	in	bone	
marrow	due	to	overgrowth	(Brigle	&	
Rogers,	2017).
• Followed	by	increased	production	of	
immunoglobulins	or	immunoglobulin	
chains	that	also	crowd	other	cells	in	bone	
marrow	(Brigle	&	Rogers,	2017).
Pathogenesis	of	abnormal	plasma	cell	
production:
• Cyclin	D	protein	dysregulation	(early	
event).
• Almost	always	a	progression	from	MGUS.	
(Brigle	&	Rogers,	2017).
• Two	karyotype	subclasses	of	MM	:
• 1.Hyperdiploid- chromosomes	
3,5,7,9,11,19,	and	21	contain	extra	copies	
or	trisomies.
• 2.	IgH	Translocation- at	14q32	of	IgH	
locus	with	the	possibility	of	various	
individual	partner	genes	that	all	result	in	
an	upregulation	of	cyclin	D	proteins.
• 40%	of	MM	cases	are	hyperdiploid	(better	
prognosis	than	patients	with	any	of	the	
various	IgH	translocation	abnormalities).
• 30%	of	MM	cases	present	with	IgH	
translocations.
• 15%	of	MM	patients	have	both	trisomies	
and	IgH	translocations.
(Brigle	&	Rogers,	2017)
Further	genetic	alterations	that	potentiate	
growth	of	abnormal	plasma	cells:
• Chromosome	13	loss
• MYC	and	RAS	oncogene	initiation
• Changes	of	chromosome	1	copies
Treatment
• Myeloablative	chemotherapy	using	two	
or	three	drug	combinations	and	
autologous	stem	cell	transplantation	
(ASCT)
Common	chemotherapy	drugs	used
• Corticosteroids:	dexamethasone,	
methylprednisolone,	prednisone
• Alkylating	agents:	Melphalan	(Alkeran),	
cyclophosphamide
• Immunomodulatory	drugs:	thalidomide,	
lenalidomide(Revlimid)
• Proteasome	inhibitors:	bortezomid	
(Velcade),	carfilzomib	(kyprolis)
(Michels	&	Peterson,	2017,	p.380)
Special	Treatment	Considerations
• Avoid	nephrotoxic	medications	and	
studies	using	contrast	media	due	to	
renal	dysfunction
• Acute	kidney	injury	with	MM:	at	least	3L	
per	day	of	intravenous	normal	saline	in	
addition	to	dexamethasone	to	decrease	
serum	light	chain	if	elevated.
(Michels	&	Peterson,	2017)
Bone	Modifying	Agents
• Zoledronic	acid	(Reclast),	pamidronate,	
denosumab	
• Refer	to	the	American	Society	of	Clinical	
Oncology’s	2017	Clinical	Practice	
Guidelines	update	cited	in	the	additional	
sources	section	for	specific	
recommendations,	selection,	dosing,	
duration,	and	monitoring	of	BMAs	with	
MM
(Anderson,	Ismaila,	&	Kyle,	2017)
High	Risk	of	Thromboembolic	Events
• Prevention	with	low-molecular-weight-
heparin	or	warfarin	with	target	INR	of	2	
to	3	(American	Society	of	Clinical	
Oncology).
• Stratify	thromboembolic	risk	factors	for	
treatment	and	consider	aspirin	alone	for	
low-risk	patients	(IMWG).
(Michels	&	Peterson,	2017,	p.380)
High	Risk	of	Recurrent	and/or	Life	
Threatening	Infection
• Vigilance	and	speed	in	recognition	and	
treatment
• May	use	prophylactic	antibiotics:
Trimethorprim/sulfamethoxazole,				
fluoroquinolone,	penicillin
• Intravenous	immune	globulin
• Prophylactic	antivirals	if	taking	
proteasome	inhibitors	due	to	risk	of	
varicella-zoster	virus
• Immunizations:	pneumococcal	
pneumonia,	Haemophilus	influenza,	
influenza	virus,	especially	for	stem	cell	
transplant	patients.
Anemia	Common	with	MM	: Restrictive	
transfusion	policy	supported	for	hemoglobin	
levels	less	than	7	g	per	dL	(Michels	&	
Peterson,	2017).
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Table	1.	Findings	on	Presentation	for	Patients	with	Multiple	Myeloma
(Michels	&	Peterson,	2017)
Implications	for	Care
Bone	marrow:	location	of	myeloma	cell	growth	
and	expansion
• 2	compartments	of	bone	marrow:	1)	cellular	
2)non-cellular
• Cellular	compartment:	hematopoietic	and	
non-hematopoietic	cells:	Myeloid	cells,	T	and	
B	lymphocytes,	natural	killer	cells	(NK),	
osteoclasts,	bone	marrow	stromal	cells,	
bone	marrow-derived	mesenchymal	stromal	
cells,	fibroblasts,	osteoblasts,	adipocytes,	
endothelial	cells,	blood	vessels
• Non-cellular	compartment:	Extracellular	
matrix,	cytokines,	chemokines,	growth	
factors,	exosomes	produced	by	cellular	
compartment.
• Both	compartments	and	their	interactions	
crucial	to	MM	progression
(Brigle	&	Rogers,	2017)
Significance	of	Pathophysiology:	Bone	
Marrow	Microenvironment	
Bone	marrow	stromal	cells:	adhere	to	MM	cells	
and,	“support	tumor	cell	proliferation,	
migration,	drug	resistance,	and	expression	of	
anti-apoptotic	proteins”	(Rigle	&	Rogers,	2017,	
p.	227)
• Activate	NF-kB	to	secrete	cytokines	which	
enhances	the	growth,	adhesion,	and	
overproduction	of	MM	cells.
• Interleukin	(IL)-6	a	major	cytokine	involved	
in	vascular	endothelial	growth	factor	
(VEGF)	secretin	which	increases	vascularity	
inside	the	bone	marrow.
• Enable	microRNAs	(miRNAs)	to	promote	
MM	cell	growth	and	overproduction	
through	exosome	release,	also	may	have	
effect	on	drug	resistance
(Brigle	&	Rogers,	2017)
Bone	marrow-derived	mesenchymal	stem	
cells
• “pluripotent	potential”	(can	develop	into	
fibroblasts,	adipocytes,	osteoblasts.	
(Rigle	&	Rogers,	2017,	p.	228)
• Support	growth	and	overproduction	of	
MM	cells	through	secretion	of	adhesion	
molecules,	cytokines,	and	chemokines.
Osteoblast	and	Osteoclast	activity
• Osteoblast	suppression
• Osteoclast	activation	due	to	MM	cell	
secretion	of	cytokines.	IL-6	secretion	by	
osteoclast	stimulates	further	MM	cell	
proliferation
• Overall	increase	of	osteolysis	leading	to	
bone	lesions	(Figure	1).
• Therapy	targeting	osteoclasts	is	key	in	
major	reduction	or	delay	in	skeletal	
pathology	related	to	MM.
(Brigle	&	Rogers,	2017)
Adipocytes
• Secrete	leptin,	adiponectin,	IL-6	which	are	
involved	in	MM	cell	growth.
• Large	quantity	of	adipocytes	in	bone	marrow
Endothelial	Cells
• Promote	neovascularization	in	bone	marrow
• Contribute	to	overproduction	of	MM	cells	
by	supplying	massive	quantity	of	IL-6.
Immune	System	Alterations
• Increase	in	immunosuppressive	cells	(CD4+	
Tregs
• Enhanced	in	bone	marrow	because	of	
increased	levels	of	IL-6	and	a	growth	
factor.
• Encourage	osteoclast	proliferation	
• Increase	in	apoptotic	ligands	and	receptors
• Decrease,	suppression,	and	alternation	of	
function	in	antitumor	mediated	cells	(CD8+	
cytotoxic	T	cells	and	NK	cells)
(Brigle	&	Rogers,	2017)
Nonspecific:	
• nausea,	vomiting,	weakness,	fatigue,	
weight	loss,	recurrent	infections,	
anemia,	bone	pain,	renal	dysfunction,	
hypercalcemia,	pathologic	fractures.	
Refer	to	Table	1	(Michels	&	Peterson,	
2017).
Asymptomatic
• Patients	may	present	without	symptoms	
but	MM	is	then	discovered	by	laboratory	
analysis	and	findings	of	hypercalcemia,	
proteinuria,	and	anemia.	(Michels	&	
Peterson,	2017)
Long	Term	Effects:	Serum	Hyperviscosity	and	
dysfunctional	plasma	cell	infiltration	and	
production	of	monoclonal	light	chains	leads	
to	end	organ	damage	(Michels	&	Peterson,	
2017).
Diagnostic	Criteria	
According	to	Michels	
and	Peterson,	2017:
“Both	criteria	must	be	met:	
(1) Clonal	bone	marrow	plasma	cells	≥	10%	
or	biopsy-proven	bony	or	extramedullary	
plasmacytoma 
(2) Any	one	or	more	of	the	following	
myeloma-defining	events: Evidence	of	
end-organ	damage	that	can	be	
attributed	to	the	underlying	plasma	cell	
proliferative	disorder,	 specifically:	
Hypercalcemia:	serum	calcium	>	1	mg	per	
dL	(0.25	mmol	per	L)	higher	than	the	upper	
limit	of	normal	or	>	11	mg	per	dL	(>	2.75	
mmol	per	L)	
Renal	insufficiency:	creatinine	clearance	<	
40	mL	per	minute	per	1.73	m2	(0.67	mL	per	
second	per	m2)	or	serum	creatinine	>	2	mg	
per	dL	(177	μmol	per	L)	
Anemia:	hemoglobin	>	2	g	per	dL	(20	g	per	
L)	below	the	lower	limit	of	normal,	or	a	
hemoglobin	value	<	10	g	per	dL	(100	g	per	L)	
Bone	lesions:	one	or	more	osteolytic	
lesions	on	skeletal	radiography,	CT,	or	
positron	emission	tomography/CT	Clonal	
bone	marrow	plasma	cells	≥	60% Involved:	
uninvolved	serum	free	light	chain	ratio	≥	100	
(involved	free	light	chain	level	must	be	≥	100	
mg	per	L)	More	than	one	focal	lesion	on	MRI	
studies	(≥	5	mm	size)	“	(p.	376,	Table	3).
Implications	for	Care
Figure	1.	MM	Bone	Lesions
Symptom	or	Laboratory	Finding Percentage	of	Patients	
Anemia	(hemoglobin	<	12	g	per	dL	
[120	g	per	L])	
73
Bone	pain	 58
Elevated	creatinine	(>	1.3	mg	per	dL	
[115	μmol	per	L])	
48
Fatigue	or	generalized	weakness	 32
Hypercalcemia	(calcium	>	10.1	mg	per	
dL	[2.52	mmol	per	L])	
28
Weight	loss 24
• Demise	of	TP53	tumor	suppressor	
activity	(can	indicate	poor	prognosis)
• Nuclear	Factor	kB	(NF-kB)	regulation	is	
inactivated	by	mutations	(presents	late	
in	disease	stage).	
• Adhesion	molecules	between	MM	cells	
and	bone	marrow	stroma	cells	
regulated	by	NF-kN	cells.	
Downregulation	results	in	MM	cell	
growth	outside	of	bone	marrow	and	
“development	of	stromal-independent	
plasma	cell	Leukemia”	(Brigle	&	Rogers,	
2017,	p.	226).
Changes	not	related	to	gene	sequencing	
(epigenetic	events):
• DNA	hypomethylation	and	
hypermethylation	in	early	progression	
of	MGUS	to	MM	and	late	stage	MM	
respectively.
• Target	genes	related	to	DNA	
methylation	include	links	to,	
“dexamethasone	resistance,	cell	
adhesion,	and	cell	signaling”	(Brigle	&	
Rogers,	2017,	p.	227).
• Increase	in	oncogene	transcription	and	
expression	as	result	of	histone	
demethylation.
(Brigle	&	Rogers,	2017)
Disease	progression	related	to	genetic	
complexity:
• Clonal	evolution:	clonal	competition,	
survival	of	the	fittest	clone.
• Clones	are	more	genetically	complex	
and	produce	a	dominant	cell	line	as	a	
result	of	diversity	and	aggression.
(Brigle	&	Rogers,	2017)
International	Staging	System	using	serum	
beta2-microglobulin	and	albumin	levels
• International	Myeloma	Working	Group	(IMWG)	
recently	presented	new	Revised	International	
Staging	System	to	include	chromosomal	
alterations.	Predicts,	“progression	free	and	
overall	survival	and	has	been	recommended	for	
use	in	future	studies”.	(Michels	&	Peterson,	
2017,	p.378)
